MX2022016536A - Tratamiento del síndrome de x frágil con cannabidiol. - Google Patents
Tratamiento del síndrome de x frágil con cannabidiol.Info
- Publication number
- MX2022016536A MX2022016536A MX2022016536A MX2022016536A MX2022016536A MX 2022016536 A MX2022016536 A MX 2022016536A MX 2022016536 A MX2022016536 A MX 2022016536A MX 2022016536 A MX2022016536 A MX 2022016536A MX 2022016536 A MX2022016536 A MX 2022016536A
- Authority
- MX
- Mexico
- Prior art keywords
- fragile
- syndrome
- cannabidiol
- treatment
- symptoms
- Prior art date
Links
- 208000001914 Fragile X syndrome Diseases 0.000 title abstract 3
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title abstract 2
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title abstract 2
- 229950011318 cannabidiol Drugs 0.000 title abstract 2
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title abstract 2
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 230000011987 methylation Effects 0.000 abstract 1
- 238000007069 methylation reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente tecnología se refiere a un método para tratar uno o más síntomas del Síndrome de X Frágil de Metilación Completa (Fmet) en un sujeto que incluye administrar una cantidad efectiva de cannabidiol al sujeto de manera que se tratan uno o más síntomas del Síndrome de X Frágil.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063045664P | 2020-06-29 | 2020-06-29 | |
| PCT/IB2021/055772 WO2022003541A1 (en) | 2020-06-29 | 2021-06-28 | Treatment of fragile x syndrome with cannabidiol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022016536A true MX2022016536A (es) | 2023-03-15 |
Family
ID=76797036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016536A MX2022016536A (es) | 2020-06-29 | 2021-06-28 | Tratamiento del síndrome de x frágil con cannabidiol. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20210401769A1 (es) |
| EP (1) | EP4171528A1 (es) |
| JP (1) | JP2023532880A (es) |
| KR (1) | KR20230031317A (es) |
| CN (1) | CN115812000A (es) |
| AU (1) | AU2021301406A1 (es) |
| BR (1) | BR112022026044A2 (es) |
| CA (1) | CA3183065A1 (es) |
| IL (1) | IL299399A (es) |
| JO (1) | JOP20220338A1 (es) |
| MX (1) | MX2022016536A (es) |
| TW (1) | TW202216127A (es) |
| WO (1) | WO2022003541A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200058513A (ko) | 2017-09-28 | 2020-05-27 | 지네르바 파마슈티컬스, 인코포레이티드 | 칸나비디올을 이용한 취약 x 증후군의 치료 |
| AU2022373753A1 (en) * | 2021-10-22 | 2024-05-09 | Zynerba Pharmaceuticals, Inc. | Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2424525A1 (en) | 2009-04-28 | 2012-03-07 | AllTranz Inc. | Formulations of cannabidiol and methods of using the same |
| GB2549277B (en) * | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder |
| GB2549278B (en) * | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Use of cannabidivarin in the treatment of autism spectrum disorder |
| KR20200054171A (ko) * | 2017-08-14 | 2020-05-19 | 지네르바 파마슈티컬스, 인코포레이티드 | 경피 칸나비디올 겔을 이용한 골관절염의 치료 방법 |
| KR20200058513A (ko) * | 2017-09-28 | 2020-05-27 | 지네르바 파마슈티컬스, 인코포레이티드 | 칸나비디올을 이용한 취약 x 증후군의 치료 |
-
2021
- 2021-06-28 WO PCT/IB2021/055772 patent/WO2022003541A1/en active Application Filing
- 2021-06-28 KR KR1020237003118A patent/KR20230031317A/ko unknown
- 2021-06-28 JP JP2022580386A patent/JP2023532880A/ja active Pending
- 2021-06-28 IL IL299399A patent/IL299399A/en unknown
- 2021-06-28 CA CA3183065A patent/CA3183065A1/en active Pending
- 2021-06-28 AU AU2021301406A patent/AU2021301406A1/en active Pending
- 2021-06-28 EP EP21737789.4A patent/EP4171528A1/en active Pending
- 2021-06-28 MX MX2022016536A patent/MX2022016536A/es unknown
- 2021-06-28 TW TW110123499A patent/TW202216127A/zh unknown
- 2021-06-28 CN CN202180045901.0A patent/CN115812000A/zh active Pending
- 2021-06-28 BR BR112022026044A patent/BR112022026044A2/pt unknown
- 2021-06-28 JO JOP/2022/0338A patent/JOP20220338A1/ar unknown
- 2021-06-28 US US17/360,781 patent/US20210401769A1/en not_active Abandoned
-
2023
- 2023-10-09 US US18/483,401 patent/US20240122873A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022003541A1 (en) | 2022-01-06 |
| JP2023532880A (ja) | 2023-08-01 |
| EP4171528A1 (en) | 2023-05-03 |
| AU2021301406A8 (en) | 2023-03-30 |
| CN115812000A (zh) | 2023-03-17 |
| CA3183065A1 (en) | 2022-01-06 |
| JOP20220338A1 (ar) | 2023-01-30 |
| KR20230031317A (ko) | 2023-03-07 |
| TW202216127A (zh) | 2022-05-01 |
| US20210401769A1 (en) | 2021-12-30 |
| IL299399A (en) | 2023-02-01 |
| AU2021301406A1 (en) | 2023-02-02 |
| BR112022026044A2 (pt) | 2023-03-07 |
| US20240122873A1 (en) | 2024-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012424A (es) | Tratamiento del sindrome del cromosoma x fragil con canabidiol. | |
| MX2022016536A (es) | Tratamiento del síndrome de x frágil con cannabidiol. | |
| MY192043A (en) | Immunoreceptor modulation for treating cancer and viral infections | |
| CA2909335C (en) | Fenfluramine for use in the treatment of dravet syndrome | |
| MX2018001435A (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| WO2013154647A3 (en) | Il-12 for radiation protection and radiation-induced toxicity mitigation | |
| NZ620486A (en) | Processing biomass | |
| EA201692408A1 (ru) | Способ обработки сапфирового материала пучком одно- и/или многозарядных ионов газа для получения антибликового материала | |
| MX2022013749A (es) | Metodos y composiciones para el tratamiento del coronavirus 2 del sindrome respiratorio agudo severo (sars-cov-2). | |
| WO2019067405A3 (en) | FORMULATION OF FENFLURAMINE COMPATIBLE WITH A CÉTOGENEOUS REGIMEN | |
| MX2022013081A (es) | Compuestos para el tratamiento de sars. | |
| BR112019005040A2 (pt) | aplicação de pridopidina para tratamento de síndrome de rett | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| WO2022119858A8 (en) | Compounds for the treatment of sars | |
| BR112018008839A8 (pt) | métodos e composições para o tratamento da amiloidose | |
| BR112015015646A2 (pt) | método para tratar biologicamente água residual com biomassa e intensificar o potencial de acúmulo de poli-hidroxialcanoato (pha) da biomassa | |
| MX2017016337A (es) | Tratamiento de carcinoma de linea media nut. | |
| MX2023006651A (es) | Tratamiento de la hemofilia con fitusirán. | |
| MX2021010884A (es) | Tratamiento de la influenza con derivados de piridona policiclica sustituida y profarmacos de los mismos en un sujeto que tiene influenza y factor de riesgo de complicacion. | |
| MX2017014743A (es) | Metodo para reducir o inactivar contenido viral o microbiano en los procesos para la fabricacion de pancreatina. | |
| MX2009004142A (es) | Metodo para prevenir o tratar sindrome metabolico. | |
| MX2022010960A (es) | Métodos y composiciones para tratar el trastorno por uso de cannabis y mitigar la abstinencia de cannabinoides. | |
| MX2021007076A (es) | Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol. | |
| WO2023009834A3 (en) | Methods of treating cancer | |
| MX2022012576A (es) | Inhibidores de axl para terapia antiviral. |